Compound reference

MOTS-c Dosage Guide 2026: The Research vs Reported Use

By the Decadewise team Education only Last reviewed 19 July 2026 7 cited sources

Short answer

What it is: MOTS-c is a 16-amino-acid peptide encoded in the mitochondrial genome, first described in 2015 as a regulator of insulin sensitivity and metabolic homeostasis (Lee, Cell Metabolism).

The trial doses: there is no published human dose schedule. The only completed human trial on record tested CB4211, a MOTS-c analog: 88 subjects, results sponsor-reported in 2021, no peer-reviewed paper.

The live one: a phase 2 trial of MOTS-c itself is recruiting now, with no public dose.

The headline number: the milligram schedules we've seen online trace back to mouse studies, not human trials.

The catch: doses are written in milligrams. Syringes read in units.

Why it trips people: milligrams and units only agree once you know your vial's concentration. On one common mix, 2mg reads as 10 units; on another, 40.

The status: not FDA approved as of July 2026, with an FDA advisory review set for July 23, 2026. Every research figure comes from the cited sources, linked at the bottom.

The calculator

How it works: punch in a vial size, a water amount, a syringe type, and a dose in milligrams. It returns the concentration, the volume, and the unit count.

Units converter

Converts the numbers you type. It does not recommend a dose.

Vial amount mg Bacteriostatic water mL Syringe type Dose you want to convert mg

Concentration20 mg per mL

Volume to draw0.1 mL

Reads as10 units

Arithmetic only. Check the result against your own vial, your own reconstitution, and your own syringe before you trust any unit count.

On this page

Short answer Calculator Reported use What does the research show? Where do internet doses come from? How the units math works How many units is 2mg? What's not known yet? The safety picture How this page is sourced The disclaimer

Community reports, not a protocol

What do users report running?

The background: no published human dose exists, so every number below comes from the protocol pages and forum threads that rank for this query. Not from research.

My own log: empty on this one. I have no dated MOTS-c run, so this section reports what the community posts instead of what I did.

The posted ranges: one top-ranking protocol page describes 2.5 to 10mg per injection in its clinical range, stepping to 5 to 10mg as the maintenance range after titration. Another describes 5 to 15mg per day in beginner, mid, and advanced tiers.

The vials: 10mg and 40mg are the sizes the ranking protocol pages are built around, each with its own dosage-chart page.

The mix we kept seeing: 2mL of bacteriostatic water into a 40mg vial, then the question of how many units a 2mg amount reads as. That exact question is why the calculator on this page exists.

Community side effects: the protocol pages mention mild injection-site redness, transient nausea above 10mg, and slight hypoglycemia when combined with fasting.

None of it verified: no control groups, no published human dose-ranging study behind any of these numbers. This is a record of what people say they run, not evidence of what MOTS-c does.

Peer-reviewed research and trial records

What does the research show?

The discovery: MOTS-c entered the literature in 2015 (Lee et al., Cell Metabolism): a 16-amino-acid peptide encoded in the mitochondrial 12S rRNA, regulating insulin sensitivity and metabolic homeostasis. Its primary target organ appears to be skeletal muscle, and it works by inhibiting the folate cycle and de novo purine biosynthesis, which activates AMPK.

The catch: that paper's in vivo evidence is in mice, with cell experiments alongside. MOTS-c treatment prevented age-dependent and high-fat-diet-induced insulin resistance, and diet-induced obesity, in mouse models.

The exercise link: the major follow-up (Reynolds et al., Nature Communications, 2021) showed exercise raises the body's own MOTS-c in human skeletal muscle and in circulation. In mice, MOTS-c improved physical performance at 2, 12, and 22 months of age, and intermittent treatment started late in life (three times weekly from 23.5 months) increased physical capacity and healthspan.

Not lifespan: read that carefully. The mouse data supports physical capacity and healthspan, not lifespan extension.

The human trial record: the only completed human study on record is a phase 1a/1b trial of CB4211, a MOTS-c analog, in healthy and NAFLD subjects (NCT03998514): 88 enrolled across the program, single and multiple ascending subcutaneous doses, completed April 2021. In the 20 obese NAFLD participants of the phase 1b part, the sponsor reported statistically significant ALT, AST, and glucose improvements against placebo and a body-weight trend at four weeks, and no serious adverse events overall.

The fine print: those topline results are sponsor-reported, presented as a late-breaking conference abstract in 2021. No peer-reviewed paper of that trial exists: a PubMed search for CB4211 returns zero records.

The direct test: a phase 2a trial of MOTS-c itself (NCT07505745) is recruiting as of July 2026: 120 adults with prediabetes and overweight or obesity planned, once-daily subcutaneous MOTS-c for 12 weeks, with insulin sensitivity (Matsuda Index) and adverse events as the primary readouts. The registry lists no milligram dose.

The gap, stated plainly: no peer-reviewed human dose-ranging study of MOTS-c exists. A 2025 review of MOTS-c dosing schedules (Fang et al., Life Sciences) describes the published exogenous schedules as preclinical work.

amino acids, encoded in mitochondrial DNA

subjects in the only completed human trial record, the CB4211 analog

peer-reviewed human dose trials of MOTS-c itself, as of July 2026

120

planned enrollment in the phase 2 trial now recruiting

Lee et al., Cell Metab 2015; ClinicalTrials.gov NCT03998514 and NCT07505745; PubMed search checked 19 July 2026.

Where do the internet doses come from?

The usual dodge: most pages either ignore the question or hand you a schedule built on mouse data. We're doing neither.

What the published record contains

What it is: mouse studies on metabolism and physical capacity, one sponsor-reported phase 1 of an analog, and one phase 2 of MOTS-c itself that is still recruiting. The published dosing schedules are all preclinical.

What it is not: a human dose. Nothing in the peer-reviewed record establishes how many milligrams a person takes, how often, or for how long.

What the posts show

The conversion move: the ranking protocol pages take the animal dosing, describe it as weight-based mouse dosing around 5 to 15mg per kilogram, and present the translated result as a "research-derived" human range of 5 to 15mg per day. That translation is their move, not a finding from a human trial.

The borrowed safety line: one ranking page backs its reassurance with a safety claim up to 10mg per injection, citing an unrelated review rather than the analog's phase 1. CB4211 is a modified analog of MOTS-c, not MOTS-c, and those data never became a peer-reviewed paper.

We will not be the ones telling you which of those numbers is right for you.

The real question: first, your body, your risk tolerance, and a doctor who knows your history. What we can give you is what the research supports and the math behind a dose; the rest is yours to resolve with someone qualified.

How does the units math work?

The point: work the numbers once, in general terms, with no dose attached to you.

Example one: say a 40mg vial of MOTS-c gets reconstituted with 2mL of bacteriostatic water. That's 20mg per mL, or 20,000mcg per mL.

The syringe side: on a U-100 insulin syringe, 100 units make a mL, so each unit is 1/100th of a mL, which at this concentration is 200mcg, or 0.2mg. From there: 1mg is 5 units, 2mg is 10 units, 10mg is 50 units.

Change one thing: reconstitute the same 40mg vial with 1mL instead of 2mL. Concentration doubles to 40mg per mL.

What changes: each unit now equals 0.4mg instead of 0.2mg. The same 2mg amount is now 5 units, not 10.

Or change the vial: a 10mg vial with 2mL of water gives 5mg per mL. Each unit is 50mcg, and 2mg reads as 40 units.

The forum trap: that "10 units" someone read on a forum could be 2mg on one reconstitution and 0.5mg on another.

The two common MOTS-c vials, three reconstitutions, on a U-100 syringe

Vial	Water added	Concentration	1 unit equals	What 2mg reads as
40mg	2mL	20mg per mL (20,000mcg per mL)	0.2mg (200mcg)	10 units
40mg	1mL	40mg per mL	0.4mg	5 units
10mg	2mL	5mg per mL	0.05mg (50mcg)	40 units

Same 2mg amount, three different unit readings. The vial and the water decide the number, not the syringe.

Syringe scale, before any concentration math

Syringe	Units per mL	1 unit equals
U-100	100 units per mL	0.01mL
U-40	40 units per mL	0.025mL

At the same unit mark, the U-40 pulls 2.5x the drug the U-100 does.

The second trap: not the concentration, the syringe. Insulin syringes read in units at two scales.

The two scales: U-100 shows 100 units per mL, so one unit is 0.01mL. U-40 shows 40 units per mL, so one unit is 0.025mL.

The 2.5x problem: draw on a U-40 thinking in U-100 numbers and every unit pulls 2.5 times the volume you planned. Same vial, same concentration, same "40 units" on the barrel.

Start with the syringe in your hand, not the number on the forum.

Both halves: that is the whole milligrams-versus-units confusion, end to end. The syringe measures volume exactly. It cannot know your concentration or its own scale; you can.

How many units is 2mg of MOTS-c?

The short answer: it depends on the concentration. On the most-asked mix, a 40mg vial plus 2mL of water (20mg per mL), 2mg reads as 10 units on a U-100 syringe. The same vial plus 1mL reads 5 units; a 10mg vial plus 2mL reads 40 units.

The rule: a milligram amount has no universal units number. Concentration first, syringe type second, then the arithmetic, or run it in the calculator above.

What's not known yet?

The status: MOTS-c is investigational. Not FDA approved as of July 2026, for any indication.

The live regulatory file: MOTS-c (free base and acetate) is back before the Pharmacy Compounding Advisory Committee on July 23 to 24, 2026, with obesity and osteoporosis as the uses under evaluation; an earlier Category 2 nomination was previously withdrawn. That decision affects compounding access, not approval.

The trial pipeline: the first direct human trial of MOTS-c itself, a phase 2a in prediabetes with 120 people planned, started recruiting in February 2026 and lists a primary completion date of February 2027. Until it reads out, no published human dose exists.

The real gaps:

No peer-reviewed human dose-ranging study of MOTS-c. The one completed human trial tested an analog, and its full data never reached a journal.
No published long-term human safety data. The recruiting phase 2 lists adverse events as a primary outcome, which means the answer is still being collected.
No verified data on the community schedules (5 to 15mg a day and the rest) that dominate the search results. None of it has been studied in a controlled human trial.

Anyone who promises otherwise is guessing.

The biggest gap: in our read, one gap matters more than any figure on the page. A research-grade vial comes with no independent check on what is actually in it.

All taken on trust: identity, purity, sterility, and the concentration the label promises.

The quiet one: a mislabeled concentration breaks every units calc above without warning. The math is only as good as the label it trusts.

The real worry: that is not a question about dose, a question about the vial, and that is the one we would actually lose sleep over.

How this page is sourced

No secondary summaries: every research figure on this page comes straight from the cited sources, linked at the bottom. Not lifted from a secondary summary.

The seven sources: three peer-reviewed papers, two trial registry records, one sponsor release, and one regulator page. Pull them yourself, and check each number against theirs.

The standard: the full sourcing and citation-verification standard for this site lives on the methodology page. Any number here that ever needs correcting gets corrected there first.

Last reviewed: 19 July 2026.

1
Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. doi:10.1016/j.cmet.2015.02.009. PMID 25738459.
2
Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. doi:10.1038/s41467-020-20790-0. PMID 33473109.
3
Fang T, Han JC, Taberner A, Pham T. MOTS-c in type 2 diabetes mellitus: From risk factors to cardiac complications and potential treatment. Life Sci. 2025;382:124009. doi:10.1016/j.lfs.2025.124009. PMID 41083123.
4
ClinicalTrials.gov. A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver Disease. Sponsor: CohBar, Inc. Record: NCT03998514.
5
ClinicalTrials.gov. MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity (phase 2a, recruiting). Sponsor: Hudson Biotech. Record: NCT07505745.
6
CohBar, Inc. Second Quarter 2021 financial results and business update, August 10, 2021 (CB4211 phase 1a/1b topline, company-reported, not peer-reviewed). SEC EDGAR, exhibit 99.1.
7
U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (MOTS-c bulks-list review, day one). fda.gov meeting page.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.

It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.